FDA Approves Adcetris Combined with Chemotherapy for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma

On March 20, 2018, the U.S. Food and Drug Administration (FDA) approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.

Read the FDA announcement.